Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 May 15;90(10):4345–4349. doi: 10.1073/pnas.90.10.4345

A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

T W Moody 1, F Zia 1, M Draoui 1, D E Brenneman 1, M Fridkin 1, A Davidson 1, I Gozes 1
PMCID: PMC46507  PMID: 8389448

Abstract

The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formation was significantly inhibited by approximately 80%. In vitro, VIP (100 nM) stimulated colony formation approximately 2-fold, whereas 1 microM VIPhyb inhibited colony formation by approximately 50% when adenocarcinoma cell line NCI-H838 was used. The attenuation of tumor proliferation is receptor mediated, as VIPhyb inhibited specific 125I-labeled VIP binding to cell lines NCI-H157 and NCI-H838 with an IC50 of 0.7 microM. VIP (10 nM) increased the cAMP levels 5-fold when cell line NCI-H838 was used, and 10 microM VIPhyb inhibited the increase in cAMP caused by VIP. Northern blot analysis and radioimmunoassays have shown VIP mRNA and VIP-like immunoreactivity in NSCLC cells. These data suggest that VIP may be a regulatory peptide in NSCLC and that VIPhyb is a VIP receptor antagonist that inhibits proliferation.

Full text

PDF
4345

Images in this article

4346Fig. 1
on p.4346
4347Fig. 2
on p.4347

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battey J. F., Way J. M., Corjay M. H., Shapira H., Kusano K., Harkins R., Wu J. M., Slattery T., Mann E., Feldman R. I. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):395–399. doi: 10.1073/pnas.88.2.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bloom S. R., Christofides N. D., Delamarter J., Buell G., Kawashima E., Polak J. M. Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene. Lancet. 1983 Nov 19;2(8360):1163–1165. doi: 10.1016/s0140-6736(83)91215-1. [DOI] [PubMed] [Google Scholar]
  3. Brenneman D. E., Nicol T., Warren D., Bowers L. M. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res. 1990 Mar;25(3):386–394. doi: 10.1002/jnr.490250316. [DOI] [PubMed] [Google Scholar]
  4. Cauvin A., Vandermeers-Piret M. C., Vandermeers A., Coussaert E., de Neef P., Robberecht P., Christophe J. Rat PHI, PHI-GLY and PHV (1-42) stimulate adenylate cyclase in six rat tissue and cell membranes. Peptides. 1990 Sep-Oct;11(5):1009–1014. doi: 10.1016/0196-9781(90)90025-z. [DOI] [PubMed] [Google Scholar]
  5. Christophe J., Chatelain P., Taton G., Delhaye M., Waelbroeck M., Robberecht P. Comparison of VIP-secretin receptors in rat and human lung. Peptides. 1981;2 (Suppl 2):253–258. doi: 10.1016/0196-9781(81)90040-1. [DOI] [PubMed] [Google Scholar]
  6. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  7. Dey R. D., Shannon W. A., Jr, Said S. I. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res. 1981;220(2):231–238. doi: 10.1007/BF00210505. [DOI] [PubMed] [Google Scholar]
  8. Diamond L., Szarek J. L., Gillespie M. N., Altiere R. J. In vivo bronchodilator activity of vasoactive intestinal peptide in the cat. Am Rev Respir Dis. 1983 Nov;128(5):827–832. doi: 10.1164/arrd.1983.128.5.827. [DOI] [PubMed] [Google Scholar]
  9. Dickinson K. E., Schachter M., Miles C. M., Coy D. H., Sever P. S. Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung. Peptides. 1986 Sep-Oct;7(5):791–800. doi: 10.1016/0196-9781(86)90097-5. [DOI] [PubMed] [Google Scholar]
  10. Duckles S. P., Said S. I. Vasoactive intestinal peptide as a neurotransmitter in the cerebral circulation. Eur J Pharmacol. 1982 Mar 12;78(3):371–374. doi: 10.1016/0014-2999(82)90041-3. [DOI] [PubMed] [Google Scholar]
  11. Glowa J. R., Panlilio L. V., Brenneman D. E., Gozes I., Fridkin M., Hill J. M. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 1992 Jan 20;570(1-2):49–53. doi: 10.1016/0006-8993(92)90562-n. [DOI] [PubMed] [Google Scholar]
  12. Gozes I., Bodner M., Shani Y., Fridkin M. Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor. Peptides. 1986;7 (Suppl 1):1–6. doi: 10.1016/0196-9781(86)90156-7. [DOI] [PubMed] [Google Scholar]
  13. Gozes I., McCune S. K., Jacobson L., Warren D., Moody T. W., Fridkin M., Brenneman D. E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther. 1991 Jun;257(3):959–966. [PubMed] [Google Scholar]
  14. Gozes I., Meltzer E., Rubinrout S., Brenneman D. E., Fridkin M. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology. 1989 Dec;125(6):2945–2949. doi: 10.1210/endo-125-6-2945. [DOI] [PubMed] [Google Scholar]
  15. Gozes I., Shani Y., Rostène W. H. Developmental expression of the VIP-gene in brain and intestine. Brain Res. 1987 Jul;388(2):137–148. doi: 10.1016/s0006-8993(87)80007-0. [DOI] [PubMed] [Google Scholar]
  16. Gozes Y., Brenneman D. E., Fridkin M., Asofsky R., Gozes I. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res. 1991 Feb 1;540(1-2):319–321. doi: 10.1016/0006-8993(91)90528-4. [DOI] [PubMed] [Google Scholar]
  17. Haeder M., Rotsch M., Bepler G., Hennig C., Havemann K., Heimann B., Moelling K. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 1988 Mar 1;48(5):1132–1136. [PubMed] [Google Scholar]
  18. Haegerstrand A., Jonzon B., Dalsgaard C. J., Nilsson J. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5993–5996. doi: 10.1073/pnas.86.15.5993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hill J. M., Gozes I., Hill J. L., Fridkin M., Brenneman D. E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides. 1991 Jan-Feb;12(1):187–192. doi: 10.1016/0196-9781(91)90186-s. [DOI] [PubMed] [Google Scholar]
  20. Imanishi K., Yamaguchi K., Kuranami M., Kyo E., Hozumi T., Abe K. Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody. J Natl Cancer Inst. 1989 Feb 1;81(3):220–223. doi: 10.1093/jnci/81.3.220. [DOI] [PubMed] [Google Scholar]
  21. Ishihara T., Shigemoto R., Mori K., Takahashi K., Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 1992 Apr;8(4):811–819. doi: 10.1016/0896-6273(92)90101-i. [DOI] [PubMed] [Google Scholar]
  22. Itoh N., Obata K., Yanaihara N., Okamoto H. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature. 1983 Aug 11;304(5926):547–549. doi: 10.1038/304547a0. [DOI] [PubMed] [Google Scholar]
  23. Korman L. Y., Carney D. N., Citron M. L., Moody T. W. Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung. Cancer Res. 1986 Mar;46(3):1214–1218. [PubMed] [Google Scholar]
  24. Laburthe M., Boissard C., Chevalier G., Zweibaum A., Rosselin G. Peptide receptors in human lung tumor cells in culture: vasoactive intestinal peptide (VIP) and secretin interaction with the Calu-1 and SW-900 cell lines. Regul Pept. 1981 Aug;2(4):219–230. doi: 10.1016/0167-0115(81)90026-4. [DOI] [PubMed] [Google Scholar]
  25. Lee M., Draoui M., Zia F., Gazdar A., Oie H., Bepler G., Bellot F., Tarr C., Kris R., Moody T. W. Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. J Natl Cancer Inst Monogr. 1992;(13):117–123. [PubMed] [Google Scholar]
  26. Lee M., Jensen R. T., Huang S. C., Bepler G., Korman L., Moody T. W. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels. Peptides. 1990 Nov-Dec;11(6):1205–1209. doi: 10.1016/0196-9781(90)90153-v. [DOI] [PubMed] [Google Scholar]
  27. Leroux P., Vaudry H., Fournier A., St-Pierre S., Pelletier G. Characterization and localization of vasoactive intestinal peptide receptors in the rat lung. Endocrinology. 1984 May;114(5):1506–1512. doi: 10.1210/endo-114-5-1506. [DOI] [PubMed] [Google Scholar]
  28. Leys K., Morice A. H., Madonna O., Sever P. S. Autoradiographic localisation of VIP receptors in human lung. FEBS Lett. 1986 Apr 21;199(2):198–202. doi: 10.1016/0014-5793(86)80479-3. [DOI] [PubMed] [Google Scholar]
  29. Little C. D., Nau M. M., Carney D. N., Gazdar A. F., Minna J. D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983 Nov 10;306(5939):194–196. doi: 10.1038/306194a0. [DOI] [PubMed] [Google Scholar]
  30. Luis J., Said S. I. Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. Peptides. 1990 Nov-Dec;11(6):1239–1244. doi: 10.1016/0196-9781(90)90158-2. [DOI] [PubMed] [Google Scholar]
  31. Mahmoud S., Staley J., Taylor J., Bogden A., Moreau J. P., Coy D., Avis I., Cuttitta F., Mulshine J. L., Moody T. W. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 1;51(7):1798–1802. [PubMed] [Google Scholar]
  32. Morice A., Unwin R., Sever P. VIP as bronchodilator. Lancet. 1984 Feb 25;1(8374):457–458. doi: 10.1016/s0140-6736(84)91795-1. [DOI] [PubMed] [Google Scholar]
  33. Ohsawa K., Hayakawa Y., Nishizawa M., Yamagami T., Yamamoto H., Yanaihara N., Okamoto H. Synergistic stimulation of VIP/PHM-27 gene expression by cyclic AMP and phorbol esters in human neuroblastoma cells. Biochem Biophys Res Commun. 1985 Nov 15;132(3):885–891. doi: 10.1016/0006-291x(85)91890-x. [DOI] [PubMed] [Google Scholar]
  34. Ollerenshaw S., Jarvis D., Woolcock A., Sullivan C., Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med. 1989 May 11;320(19):1244–1248. doi: 10.1056/NEJM198905113201904. [DOI] [PubMed] [Google Scholar]
  35. Pincus D. W., DiCicco-Bloom E. M., Black I. B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature. 1990 Feb 8;343(6258):564–567. doi: 10.1038/343564a0. [DOI] [PubMed] [Google Scholar]
  36. Robberecht P., Tatemoto K., Chatelain P., Waelbroeck M., Delhaye M., Taton G., De Neef P., Camus J. C., Heuse D., Christophe J. Effects of PHI on vasoactive intestinal peptide receptors and adenylate cyclase activity in lung membranes. A comparison in man, rat, mouse and guinea pig. Regul Pept. 1982 Oct;4(5):241–250. doi: 10.1016/0167-0115(82)90117-3. [DOI] [PubMed] [Google Scholar]
  37. Rodenhuis S., van de Wetering M. L., Mooi W. J., Evers S. G., van Zandwijk N., Bos J. L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med. 1987 Oct 8;317(15):929–935. doi: 10.1056/NEJM198710083171504. [DOI] [PubMed] [Google Scholar]
  38. Rønnov-Jensen D., Gether U., Fahrenkrug J. PreproVIP-derived peptides in tissue and plasma from patients with VIP-producing tumours. Eur J Clin Invest. 1991 Apr;21(2):154–160. doi: 10.1111/j.1365-2362.1991.tb01804.x. [DOI] [PubMed] [Google Scholar]
  39. Said S. I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970 Sep 18;169(3951):1217–1218. doi: 10.1126/science.169.3951.1217. [DOI] [PubMed] [Google Scholar]
  40. Scholar E. M., Paul S. Stimulation of tumor cell growth by vasoactive intestinal peptide. Cancer. 1991 Mar 15;67(6):1561–1564. doi: 10.1002/1097-0142(19910315)67:6<1561::aid-cncr2820670617>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  41. Shaffer M. M., Carney D. N., Korman L. Y., Lebovic G. S., Moody T. W. High affinity binding of VIP to human lung cancer cell lines. Peptides. 1987 Nov-Dec;8(6):1101–1106. doi: 10.1016/0196-9781(87)90143-4. [DOI] [PubMed] [Google Scholar]
  42. Spindel E. R., Giladi E., Brehm P., Goodman R. H., Segerson T. P. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol. 1990 Dec;4(12):1956–1963. doi: 10.1210/mend-4-12-1956. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES